US Stocks
/
Kalaris Therapeutics, Inc. Share Price

Kalaris Therapeutics, Inc. Share Price

NASDAQ: KLRS | Micro Cap
$2.50
-$0.05 (-2.16%) Last updated on 09 Oct, 2026 | 01:18 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Kalaris Therapeutics, Inc. Stock Performance

Open
$2.42
Prev. Close
$2.55
Circuit Range
N/A
Day Range
$2.42 - $2.51
Year Range
$2.42 - $11.81
Volume
618
Average Traded
$2.47

Kalaris Therapeutics, Inc. Share Price Today

As of 9 October 2026, Kalaris Therapeutics, Inc.'s share price is $2.50. The stock opened at $2.42, compared to its previous close of $2.55. During today's trading session, Kalaris Therapeutics, Inc.'s share price traded between $2.42 and $2.51, with an average price of $2.46. Over the past 52 weeks, the stock has recorded a high of $11.81 and a low of $2.42. In terms of performance, Kalaris Therapeutics, Inc.'s share price has declined by 54.72% over the last six months and is down 48.66% on a year-on-year basis.

Kalaris Therapeutics, Inc. Share Price Chart

$2.42$2.51
L
Show Current Price
H

Kalaris Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$38.09M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.86
Revenue (TTM)
$0.00
Return On Equity (TTM)
-76.75%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
3.11%

Kalaris Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$11.89-$10.00-$10.86-$11.52
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A15.90%-8.60%-6.08%

Kalaris Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$43.44
Net Profit MarginN/A
Income ChangeN/A

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Kalaris Therapeutics, Inc. Historical Returns

MonthOpenCloseChange %
Oct 2026
$2.80
$2.50
-14.09%
Sep 2026
$3.91
$2.91
-30.30%
Aug 2026
$3.67
$4.17
+17.94%
Jul 2026
$4.43
$3.54
-15.61%
Jun 2026
$5.18
$4.20
-19.02%
May 2026
$5.50
$5.18
-5.99%
Apr 2026
$5.67
$5.51
-5.00%
Mar 2026
$10.45
$5.80
-43.85%
Feb 2026
$9.25
$10.33
+16.46%
Jan 2026
$8.12
$8.87
+5.34%
Dec 2025
$5.95
$8.42
+35.70%
Nov 2025
$4.81
$6.21
+27.67%

KLRS Share Price FAQs

What is Kalaris Therapeutics, Inc. share price today?

chevron-up
Kalaris Therapeutics, Inc. share price today is $2.50 as on October 9, 2026 at 1:18 am IST.

What is the 52 week high and 52 week low of Kalaris Therapeutics, Inc. stock?

chevron-up
The 52 week high of Kalaris Therapeutics, Inc. stock is $11.81, while the 52 week low is $2.42 as of 9 Oct '26.

What is KLRS's market capitalisation today?

chevron-up
KLRS market capitalisation is $38.09M as of October 9, 2026, at 6:11 pm IST.

What is KLRS's net income for the last quarter?

chevron-up
KLRS's net income for the last quarter is -11.52B USD.

What is the 5 year returns of KLRS?

chevron-up
The 5 year returns of KLRS is -99.55% as on 9 Oct '26.

What is the high & low stock price of KLRS today?

chevron-up
KLRS stock price hit a high of $2.51 and low of $2.42 as of 9 Oct '26.

Can I buy KLRS shares in India?

chevron-up
Yes. You can buy KLRS in India by opening an international trading account.